Aspergillosis Clinical Trial
Official title:
Prevalence of Chronic Pulmonary Aspergillosis and Antifungal Drug Resistance of Aspergillus Spp. in Pulmonary Tuberculosis Patients in Uzbekistan
Pulmonary tuberculosis (PTB) is the most common cause of lung destruction, contributing to coinfections development, and Aspergillosis spp. is one of the most important. Diagnosis of chronic pulmonary aspergillosis (CPA) in PTB patients is difficult due to similarity of clinical and radiological data, especially in resource-constrained settings. Differentiation of PTB patients with singling out a group with a higher Aspergillus IgG level during the initial examination will help physicians to orient to further examination of CPA. Objectives: to determine the prevalence of aspergillosis in Koch's bacillus-positive and Koch's bacillus-negative PTB patients and antifungal resistance of Aspergillus species isolates in Central Asia countries.
Chronic pulmonary aspergillosis (CPA) complicates treated pulmonary tuberculosis (PTB), with high 5-year mortality. PTB affected an estimated 10.4 million people in 2016. Just 57% of PTB cases reported to the World Health Organization (WHO) were bacteriologically confirmed. CPA both complicates and mimics treated PTB. The prevalence of CPA in patients with treated TB and the contribution of misdiagnosed CPA to PTB prevalence estimates are unclear. Mycological analysis of sputum for Aspergillus is often negative in CPA. Detection of Aspergillus IgG is one of the main analysis in CPA diagnosis, but until recently had been inadequately validated for use in this context. Both tests are infrequently available in areas of high PTB prevalence. Antifungal therapy improves survival. But, survival rates vary significantly among published studies. Reported survival rates are 58%-93% at 1 year of follow-up, 17.5%-85% at 5 years of follow-up, and 30%-50% at 10 years of follow-up. In a selected group of patients with CPA, weekly subcutaneous injections of IFNγ has been shown to improve disease control and also helps with bacterial clearance. Several factors have been reported to affect mortality, including by underlying pulmonary disease, advanced age, NTM infection, quality of life scores, and serum albumin levels. No data on the prevalence of CPA among patients with PTB and resistance of Aspergillus spp. to antifungal drugs in Uzbekistan and neighboring countries. The aim of the study is to determine the prevalence of aspergillosis in Koch's bacillus-positive and Koch's bacillus-negative PTB patients and antifungal resistance of Aspergillus species isolates in Central Asia countries. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT01887457 -
Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy
|
Phase 2 | |
Completed |
NCT00940017 -
A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects
|
Phase 4 | |
Enrolling by invitation |
NCT01617759 -
Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis
|
||
Terminated |
NCT03905447 -
The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.
|
Phase 2 | |
Recruiting |
NCT04744454 -
Post Marketing Surveillance (PMS) Study of Cresemba in Korea.
|
||
Completed |
NCT02715570 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945
|
Phase 1 | |
Withdrawn |
NCT01622595 -
UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients
|
N/A | |
Completed |
NCT00001937 -
Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients
|
Phase 3 | |
Completed |
NCT04935463 -
Mucormycosis in COVID-19
|
||
Withdrawn |
NCT01188759 -
Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects
|
Phase 3 | |
Completed |
NCT00473252 -
Surveillance of Fungal Infections During Construction Activity
|
N/A | |
Completed |
NCT00037206 -
A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).
|
Phase 2/Phase 3 | |
Completed |
NCT04818853 -
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
|
||
Completed |
NCT00412893 -
Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis
|
Phase 3 | |
Recruiting |
NCT06135597 -
Immune Regulation in Chronic Aspergillus Infection After COVID-19 Infection
|
||
Terminated |
NCT02646800 -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
|
Phase 4 | |
Completed |
NCT00854607 -
An Observational Study of Fungal Biomarkers (MK-0000-089)
|
N/A | |
Completed |
NCT00388167 -
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
|
Phase 4 | |
Completed |
NCT05065658 -
Posaconazole Prophylaxis for CAPA Prevention in Critically-Ill Patients
|
||
Completed |
NCT00005912 -
Voriconazole to Prevent Systemic Fungal Infections in Children
|
Phase 1 |